For research use only. Not for therapeutic Use.
DPO-1 is a potent inhibitor of the voltage-gated potassium channel subtype Kv1.5 and a blocker of ultrarapid delayed rectifier potassium current. DPO-1 prevents atrial arrhythmia[1][2].
| Catalog Number | I010578 |
| CAS Number | 43077-30-1 |
| Synonyms | [[(1S,2S,5R)-5-methyl-2-propan-2-ylcyclohexyl]-phenylphosphoryl]benzene |
| Molecular Formula | C22H29OP |
| Purity | ≥95% |
| InChI | InChI=1S/C22H29OP/c1-17(2)21-15-14-18(3)16-22(21)24(23,19-10-6-4-7-11-19)20-12-8-5-9-13-20/h4-13,17-18,21-22H,14-16H2,1-3H3/t18-,21+,22+/m1/s1 |
| InChIKey | BPCNGVCAHAIZEE-COPCDDAFSA-N |
| SMILES | CC1CCC(C(C1)P(=O)(C2=CC=CC=C2)C3=CC=CC=C3)C(C)C |
| Reference | [1]. Lagrutta A, et al. Novel, potent inhibitors of human Kv1.5 K+ channels and ultrarapidly activating delayed rectifier potassium current. J Pharmacol Exp Ther. 2006 Jun;317(3):1054-63. [2]. Stump GL, et al. In vivo antiarrhythmic and cardiac electrophysiologic effects of a novel diphenylphosphine oxide IKur blocker (2-isopropyl-5-methylcyclohexyl) diphenylphosphine oxide. J Pharmacol Exp Ther. 2005 Dec;315(3):1362-7. |
